<SEC-DOCUMENT>0001209191-15-071755.txt : 20150922
<SEC-HEADER>0001209191-15-071755.hdr.sgml : 20150922
<ACCEPTANCE-DATETIME>20150922110437
ACCESSION NUMBER:		0001209191-15-071755
CONFORMED SUBMISSION TYPE:	D/A
PUBLIC DOCUMENT COUNT:		1
ITEM INFORMATION:		<ITEMS>06b
FILED AS OF DATE:		20150922
DATE AS OF CHANGE:		20150922
EFFECTIVENESS DATE:		20150922

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AYTU BIOSCIENCE, INC
		CENTRAL INDEX KEY:			0001385818
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				470883144
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		D/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	021-245095
		FILM NUMBER:		151118776

	BUSINESS ADDRESS:	
		STREET 1:		373 INVERNESS PARKWAY
		STREET 2:		SUITE 200
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80112
		BUSINESS PHONE:		(720) 437-6580

	MAIL ADDRESS:	
		STREET 1:		373 INVERNESS PARKWAY
		STREET 2:		SUITE 200
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AYTU BIOSCIENCE, INC.
		DATE OF NAME CHANGE:	20150609

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Rosewind CORP
		DATE OF NAME CHANGE:	20070110
</SEC-HEADER>
<DOCUMENT>
<TYPE>D/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<edgarSubmission>

    <schemaVersion>X0707</schemaVersion>

    <submissionType>D/A</submissionType>

    <testOrLive>LIVE</testOrLive>

    <primaryIssuer>
        <cik>0001385818</cik>
        <entityName>AYTU BIOSCIENCE, INC</entityName>
        <issuerAddress>
            <street1>373 Inverness Parkway</street1>
            <street2>Suite 206</street2>
            <city>Englewood</city>
            <stateOrCountry>CO</stateOrCountry>
            <stateOrCountryDescription>COLORADO</stateOrCountryDescription>
            <zipCode>80112</zipCode>
        </issuerAddress>
        <issuerPhoneNumber>720-437-6580</issuerPhoneNumber>
        <jurisdictionOfInc>COLORADO</jurisdictionOfInc>
        <issuerPreviousNameList>
            <previousName>Rosewind Corporation</previousName>
        </issuerPreviousNameList>
        <edgarPreviousNameList>
            <previousName>AYTU BIOSCIENCE, INC.</previousName>
            <previousName>Rosewind CORP</previousName>
        </edgarPreviousNameList>
        <entityType>Corporation</entityType>
        <yearOfInc>
            <overFiveYears>true</overFiveYears>
        </yearOfInc>
    </primaryIssuer>

    <relatedPersonsList>
        <relatedPersonInfo>
            <relatedPersonName>
                <firstName>Joshua</firstName>
                <middleName>R.</middleName>
                <lastName>Disbrow</lastName>
            </relatedPersonName>
            <relatedPersonAddress>
                <street1>c/o AytuBioscience, Inc.</street1>
                <street2>373 Inverness Parkway, Suite 206</street2>
                <city>Englewood</city>
                <stateOrCountry>CO</stateOrCountry>
                <stateOrCountryDescription>COLORADO</stateOrCountryDescription>
                <zipCode>80112</zipCode>
            </relatedPersonAddress>
            <relatedPersonRelationshipList>
                <relationship>Executive Officer</relationship>
            </relatedPersonRelationshipList>
        </relatedPersonInfo>
        <relatedPersonInfo>
            <relatedPersonName>
                <firstName>Jarrett</firstName>
                <middleName>T.</middleName>
                <lastName>Disbrow</lastName>
            </relatedPersonName>
            <relatedPersonAddress>
                <street1>c/o Aytu Bioscience, Inc.</street1>
                <street2>373 Inverness Parkway, Suite 206</street2>
                <city>Englewood</city>
                <stateOrCountry>CO</stateOrCountry>
                <stateOrCountryDescription>COLORADO</stateOrCountryDescription>
                <zipCode>80112</zipCode>
            </relatedPersonAddress>
            <relatedPersonRelationshipList>
                <relationship>Executive Officer</relationship>
            </relatedPersonRelationshipList>
            <relationshipClarification></relationshipClarification>
        </relatedPersonInfo>
        <relatedPersonInfo>
            <relatedPersonName>
                <firstName>Gregory</firstName>
                <middleName>A.</middleName>
                <lastName>Gould</lastName>
            </relatedPersonName>
            <relatedPersonAddress>
                <street1>c/o Aytu Bioscience, Inc.</street1>
                <street2>373 Inverness Parkway, Suite 206</street2>
                <city>Englewood</city>
                <stateOrCountry>CO</stateOrCountry>
                <stateOrCountryDescription>COLORADO</stateOrCountryDescription>
                <zipCode>80112</zipCode>
            </relatedPersonAddress>
            <relatedPersonRelationshipList>
                <relationship>Executive Officer</relationship>
            </relatedPersonRelationshipList>
            <relationshipClarification></relationshipClarification>
        </relatedPersonInfo>
        <relatedPersonInfo>
            <relatedPersonName>
                <firstName>Michael</firstName>
                <lastName>Macaluso</lastName>
            </relatedPersonName>
            <relatedPersonAddress>
                <street1>c/o Aytu Bioscience, Inc.</street1>
                <street2>373 Inverness Parkway, Suite 206</street2>
                <city>Englewood</city>
                <stateOrCountry>CO</stateOrCountry>
                <stateOrCountryDescription>COLORADO</stateOrCountryDescription>
                <zipCode>80112</zipCode>
            </relatedPersonAddress>
            <relatedPersonRelationshipList>
                <relationship>Director</relationship>
            </relatedPersonRelationshipList>
            <relationshipClarification></relationshipClarification>
        </relatedPersonInfo>
    </relatedPersonsList>

    <offeringData>
        <industryGroup>
            <industryGroupType>Pharmaceuticals</industryGroupType>
        </industryGroup>
        <issuerSize>
            <revenueRange>Decline to Disclose</revenueRange>
        </issuerSize>
        <federalExemptionsExclusions>
            <item>06b</item>
        </federalExemptionsExclusions>
        <typeOfFiling>
            <newOrAmendment>
                <isAmendment>true</isAmendment>
                <previousAccessionNumber>0001209191-15-063890</previousAccessionNumber>
            </newOrAmendment>
            <dateOfFirstSale>
                <value>2015-08-31</value>
            </dateOfFirstSale>
        </typeOfFiling>
        <durationOfOffering>
            <moreThanOneYear>false</moreThanOneYear>
        </durationOfOffering>
        <typesOfSecuritiesOffered>
            <isDebtType>true</isDebtType>
        </typesOfSecuritiesOffered>
        <businessCombinationTransaction>
            <isBusinessCombinationTransaction>false</isBusinessCombinationTransaction>
            <clarificationOfResponse></clarificationOfResponse>
        </businessCombinationTransaction>
        <minimumInvestmentAccepted>0</minimumInvestmentAccepted>
        <salesCompensationList>
            <recipient>
                <recipientName>Newbridge Securities Corporation</recipientName>
                <recipientCRDNumber>104065</recipientCRDNumber>
                <associatedBDName>None</associatedBDName>
                <associatedBDCRDNumber>None</associatedBDCRDNumber>
                <recipientAddress>
                    <street1>1451 Cypress Creek Road, Suite 204</street1>
                    <city>Ft. Lauderdale</city>
                    <stateOrCountry>FL</stateOrCountry>
                    <stateOrCountryDescription>FLORIDA</stateOrCountryDescription>
                    <zipCode>33309</zipCode>
                </recipientAddress>
                <statesOfSolicitationList></statesOfSolicitationList>
            </recipient>
        </salesCompensationList>
        <offeringSalesAmounts>
            <totalOfferingAmount>6000000</totalOfferingAmount>
            <totalAmountSold>5175000</totalAmountSold>
            <totalRemaining>825000</totalRemaining>
            <clarificationOfResponse></clarificationOfResponse>
        </offeringSalesAmounts>
        <investors>
            <hasNonAccreditedInvestors>false</hasNonAccreditedInvestors>
            <totalNumberAlreadyInvested>96</totalNumberAlreadyInvested>
        </investors>
        <salesCommissionsFindersFees>
            <salesCommissions>
                <dollarAmount>244000</dollarAmount>
            </salesCommissions>
            <findersFees>
                <dollarAmount>0</dollarAmount>
            </findersFees>
            <clarificationOfResponse></clarificationOfResponse>
        </salesCommissionsFindersFees>
        <useOfProceeds>
            <grossProceedsUsed>
                <dollarAmount>0</dollarAmount>
            </grossProceedsUsed>
            <clarificationOfResponse>Other than the payment of salaries and other compensation and benefits, no officer, director, or promoter will receive any payments from the proceeds of this offering.</clarificationOfResponse>
        </useOfProceeds>
        <signatureBlock>
            <authorizedRepresentative>false</authorizedRepresentative>
            <signature>
                <issuerName>AYTU BIOSCIENCE, INC</issuerName>
                <signatureName>/s/ Gregory A. Gould</signatureName>
                <nameOfSigner>Gregory A. Gould</nameOfSigner>
                <signatureTitle>Chief Financial Officer</signatureTitle>
                <signatureDate>2015-09-21</signatureDate>
            </signature>
        </signatureBlock>
    </offeringData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
